A multicenter, prospective, phase II trial of second-line aflibercept plus FOLFIRI in patients with metastatic colorectal cancer refractory to an anti-EGFR antibody: HGCSG1801.
Nakatsumi H, Komatsu Y, Harada K, Kawamoto Y, Yuki S, Sawada K, Ishiguro A, Sogabe S, Ando T, Sasaki Y, Yoshikawa A, Nakamura M, Dazai M, Tateyama M, Muto O, Kotaka M, Sagawa T, Muranaka T, Hatanaka K, Takagi R, Sakata Y.
Nakatsumi H, et al. Among authors: hatanaka k.
Int J Cancer. 2024 Dec 15;155(12):2223-2231. doi: 10.1002/ijc.35116. Epub 2024 Aug 14.
Int J Cancer. 2024.
PMID: 39143041
Clinical Trial.